The applicability of targeting MDM2 extends beyond tumors with wild-type p53, as it maintains significant oncogenic potency in p53-deficient cancers through alternative signaling pathways (Nag et al., 2013; Nag et al., 2014; Wang W. et al., 2024). This evidence concerns the gene TP53 and cancer.